Dr. Huang founded Ascendia in 2012 after a career in pharmaceutical R&D and management at Pfizer, Baxter, AstraZeneca, and most recently Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. Dr. Huang holds a Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with Joseph B. Schwartz.
Dr. Huang’s research interests are centered on improvement of solubility and dissolution for, and controlled delivery of, poorly water soluble drugs through nano-emulsion, nano-particle and amorphous solid dispersion technologies. His publications include studies on drug solubilization and controlled delivery in polymeric solid dispersion systems, amorphous drug delivery systems, controlled release, modeling and simulation, thermal and spectroscopic characterization of amorphous molecular dispersions, drug-polymer interactions and its significance on physical stability of amorphous drug, and micro/nano particulates for use in parenteral dosage forms. He has been a reviewer for the Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, Journal of Controlled Release, Drug Development and Industrial Pharmacy, PDA Journal of Pharmaceutical Science and Technology, Molecular Pharmaceutics, and Pharmaceutical Research. Currently, he is a member of American Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).